SEC Form 4 · accession 0001562180-16-002140
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen Kanes
Officer — Chief Medical Officer
Period of report
Apr 19, 2016
Accepted (ET)
Apr 21, 2016 · 1:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Apr 19, 2016 | S | 21,000 | $38.00 | D | 25,948 | D | |
| Common Stock | Apr 20, 2016 | M | 21,000 | $0.45 | A | 46,948 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $0.45 | Apr 20, 2016 | M | 21,000 | D | — | Jul 23, 2023 | Common Stock | 21,000 | 112,100 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- F2This transaction was executed in multiple trades at prices ranging from $38.00 USD to $38.01 USD. The price reported above reflects the weighted average sale price.
- F325% 1 year cliff then evenly for the remaining 36 months beginning on 18-Jul-2013.